UK regulator reviewing AstraZeneca's US$39bil Alexion buyout

The UK's Competition and Markets Authority (CMA) said on Tuesday it was inviting comments from any interested party on the deal to help its assessment, a routine carried out for major deals, and set a deadline of June 3 for any submissions

LONDON: Britain's competition regulator is reviewing AstraZeneca's planned US$39 billion takeover of U.S.-based Alexion on whether it could reduce competition in Britain or other markets.

The UK's Competition and Markets Authority (CMA) said on Tuesday it was inviting comments from any interested party on the deal to help its assessment, a routine carried out for major deals, and set a deadline of June 3 for any submissions.